New GSK-Verily JV Aims For Smart, 'Grain Of Rice' Neuromod Tech

Galvani Bioelectronics, the new joint venture between Google’s health-care spinoff Verily and drug giant GSK, will develop a new generation of "bioelectronic medicines" – neuromodulating therapies to treat a wide range of chronic diseases. Brian Otis, CTO of Verily, tells Medtech Insight how the devices that will come out of Galvani differ from existing neuromodulation technologies.

Active Receptor

GlaxoSmithKline PLC and Verily Life Sciences are to invest up to £540m ($717m) over the next seven years in Galvani Bioelectronics, a new joint venture dedicated to breaching the next frontier in neuromodulation technologies.

The joint venture is not GSK's first foray in this field; the drugs giant set up a dedicated "bioelectronic medicines"...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business